TY - JOUR
T1 - Recommendations for Clinical CYP2D6 Genotyping Allele Selection
T2 - A Joint Consensus Recommendation of the Association for Molecular Pathology, College of American Pathologists, Dutch Pharmacogenetics Working Group of the Royal Dutch Pharmacists Association, and the European Society for Pharmacogenomics and Personalized Therapy
AU - Pratt, Victoria M.
AU - Cavallari, Larisa H.
AU - Del Tredici, Andria L.
AU - Gaedigk, Andrea
AU - Hachad, Houda
AU - Ji, Yuan
AU - Kalman, Lisa V.
AU - Ly, Reynold C.
AU - Moyer, Ann M.
AU - Scott, Stuart A.
AU - van Schaik, R. H.N.
AU - Whirl-Carrillo, Michelle
AU - Weck, Karen E.
N1 - Funding Information:
Disclosures: The Pharmacogenomics Laboratory, Indiana University School of Medicine; Medical Genetics Laboratory, University of North Carolina; Millennium Health; Mayo Clinic Laboratories; and the Stanford Medicine Clinical Genomics Laboratory are fee-for-service clinical laboratories that offer clinical pharmacogenetic testing. V.M.P. has received research funding from Implementing Genomics in Practice project grant U01 HG010245 . A.L.D. is a former employee of Millennium Health, LLC. S.A.S. has received consultant's fees from Sema4. H.H. is s former employee and holds stock options in Translational Software, a PGx interpretative service. L.H.C. has received research funding from NIH/ National Human Genome Research Institute grant U01 HG007269 and NIH/ National Center for Advancing Translational Sciences grant UL1 TR001427 . M.W.C. has received research funding from NIH/NHGRI/NICHD grant U24 HG010615 and NIH/ NHGRI grant U24 HG010135 , a member of the Clinical Pharmacogenetics Implementation Consortium. A.M.M. is a member of the College of American Pathologists/American College of Medical Genetics and Genomics Biochemical and Molecular Genetics Committee and Pharmacogenetics Workgroup. R.H.N.v.S is a member of the Dutch Pharmacogenetics Working Group of the Royal Dutch Pharmacists Association, and president of the European Society for Pharmacogenomics and Personalized Therapy. K.E.W. has received research funding from NIH/ National Human Genome Research Institute grant U01 HG006487-05 and NIH/ NHGRI grant ∗ 2R01HD055651-11 . A.G. has received research funding from NIH/ National Institute of General Medical Sciences grant R24 GM123930 and is the director of PharmVar and a member of CPIC. R.C.L is a member of the Pharmacogene Variation Consortium.
Funding Information:
Supported exclusively by the Association for Molecular Pathology.Disclosures: The Pharmacogenomics Laboratory, Indiana University School of Medicine; Medical Genetics Laboratory, University of North Carolina; Millennium Health; Mayo Clinic Laboratories; and the Stanford Medicine Clinical Genomics Laboratory are fee-for-service clinical laboratories that offer clinical pharmacogenetic testing. V.M.P. has received research funding from Implementing Genomics in Practice project grant U01 HG010245. A.L.D. is a former employee of Millennium Health, LLC. S.A.S. has received consultant's fees from Sema4. H.H. is s former employee and holds stock options in Translational Software, a PGx interpretative service. L.H.C. has received research funding from NIH/National Human Genome Research Institute grant U01 HG007269 and NIH/National Center for Advancing Translational Sciences grant UL1 TR001427. M.W.C. has received research funding from NIH/NHGRI/NICHD grant U24 HG010615 and NIH/NHGRI grant U24 HG010135, a member of the Clinical Pharmacogenetics Implementation Consortium. A.M.M. is a member of the College of American Pathologists/American College of Medical Genetics and Genomics Biochemical and Molecular Genetics Committee and Pharmacogenetics Workgroup. R.H.N.v.S is a member of the Dutch Pharmacogenetics Working Group of the Royal Dutch Pharmacists Association, and president of the European Society for Pharmacogenomics and Personalized Therapy. K.E.W. has received research funding from NIH/National Human Genome Research Institute grant U01 HG006487-05 and NIH/NHGRI grant ∗2R01HD055651-11. A.G. has received research funding from NIH/National Institute of General Medical Sciences grant R24 GM123930 and is the director of PharmVar and a member of CPIC. R.C.L is a member of the Pharmacogene Variation Consortium.
Publisher Copyright:
© 2021 Association for Molecular Pathology and American Society for Investigative Pathology
PY - 2021/9
Y1 - 2021/9
N2 - The goals of the Association for Molecular Pathology Clinical Practice Committee's Pharmacogenomics (PGx) Working Group are to define the key attributes of pharmacogenetic alleles recommended for clinical testing, and to determine a minimal set of variants that should be included in clinical PGx genotyping assays. This document series provides recommendations on a minimal panel of variant alleles (Tier 1) and an extended panel of variant alleles (Tier 2) that will aid clinical laboratories in designing assays for PGx testing. When developing these recommendations, the Association for Molecular Pathology PGx Working Group considered the functional impact of the variant alleles, allele frequencies in multiethnic populations, the availability of reference materials, as well as other technical considerations with regard to PGx testing. The ultimate goal of this Working Group is to promote standardization of PGx gene/allele testing across clinical laboratories. This document is focused on clinical CYP2D6 PGx testing that may be applied to all cytochrome P450 2D6–metabolized medications. These recommendations are not meant to be interpreted as prescriptive but to provide a reference guide for clinical laboratories that may be either implementing PGx testing or reviewing and updating their existing platform.
AB - The goals of the Association for Molecular Pathology Clinical Practice Committee's Pharmacogenomics (PGx) Working Group are to define the key attributes of pharmacogenetic alleles recommended for clinical testing, and to determine a minimal set of variants that should be included in clinical PGx genotyping assays. This document series provides recommendations on a minimal panel of variant alleles (Tier 1) and an extended panel of variant alleles (Tier 2) that will aid clinical laboratories in designing assays for PGx testing. When developing these recommendations, the Association for Molecular Pathology PGx Working Group considered the functional impact of the variant alleles, allele frequencies in multiethnic populations, the availability of reference materials, as well as other technical considerations with regard to PGx testing. The ultimate goal of this Working Group is to promote standardization of PGx gene/allele testing across clinical laboratories. This document is focused on clinical CYP2D6 PGx testing that may be applied to all cytochrome P450 2D6–metabolized medications. These recommendations are not meant to be interpreted as prescriptive but to provide a reference guide for clinical laboratories that may be either implementing PGx testing or reviewing and updating their existing platform.
UR - http://www.scopus.com/inward/record.url?scp=85113366432&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85113366432&partnerID=8YFLogxK
U2 - 10.1016/j.jmoldx.2021.05.013
DO - 10.1016/j.jmoldx.2021.05.013
M3 - Review article
C2 - 34118403
AN - SCOPUS:85113366432
VL - 23
SP - 1047
EP - 1064
JO - Journal of Molecular Diagnostics
JF - Journal of Molecular Diagnostics
SN - 1525-1578
IS - 9
ER -